FDA
-
-
-
-
-
-
-
H.C. Wainwright Reiterates Buy Rating on BridgeBio Pharma (BBIO)
-
-
-
-
-
-
-
BridgeBio Raises $1 Billion in Preferred Equity to Accelerate Present and Upcoming Launches
-
-
-
-
-
-
-
BridgeBio Submits NDA to FDA for Encaleret for Individuals Living with ADH1
-
-
-
-
-
-
-
H.C. Wainwright Reiterates Buy Rating on BridgeBio Pharma (BBIO)
-
-
-
-
-
-
-
BridgeBio reports positive phase 3 results for LGMD2I/R9 drug BBP-418
-
-
-
-
-
-
-
BridgeBio Announces Commercial Progress, Program Updates, and 2026 Milestones at the 44th Annual J.P. Morgan Healthcare Conference
-
-
-
-
-
-
-
BridgeBio reports positive phase 3 results for encaleret in rare disease
-
330,519 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

